icon-folder.gif   Conference Reports for NATAP  
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
Safety and Efficacy of Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV Genotype 3 Infection: Interim Results of a Multicenter European Compassionate Use Program
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
Here are reported the interim findings on the combination of DCV + SOF ± RBV in HCV GT 3-infected patients with advanced liver disease enrolled in the European DCV compassionate use program (CUP; AI444-237) ......patients were at high risk of hepatic decompensation or death within 12 months if left untreated -Or urgent need of viral clearance, (extrahepatic
manifestations/comorbidities)....about 60% had received prior HCV
therapy....median age 55....82-90% had cirrhosis....about 50% had Child-Pugh A, 40% Child-Pugh B and 6-18% Child-Pugh C....median platelet count 75-85 x 109/La And 15% had HIV as well....4-10% had received liver transplant....SVR Rates were 86% with DCV+Sof, 88% with DCV+Sof+rbv, patients with cirrhosis had the same SVR rates, see below for full set of SVR rates and safety.
Welzel TM,1 Petersen J,2 Ferenci P,3 Gschwantler M,4 Herzer K,5 Cornberg M,6 Schott E,7 Berg T,8 Spengler U,9 Weiland O,10 van der Valk M,11 Geier A,12 Rockstroh JK,9 Peck-Radosavljevic M,3 Zhao Y,13 Jimenez-Exposito MJ,14 Zeuzem S1 1Universitatsklinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany; 2IFI Institut fur Interdisziplinare Medizin, Hamburg, Germany; 3Medizinische Universitat Wien, Vienna, Austria; 4Wilhelminenspital, Vienna, Austria; 5Universitatsklinikum Essen (AoR), Essen, Germany; 6Medizinische Hochschule Hannover, Hannover, Germany; 7Charité Universitatmedizin Berlin, Berlin, Germany; 8Universitatsklinikum Leipzig, Leipzig, Germany; 9Universitatsklinikum Bonn, Bonn, Germany; 10Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; 11Academic Medical Center, Amsterdam, Netherlands; 12Universitatsklinikum Wurzburg, Wurzburg, Germany; 13Bristol-Myers Squibb, Hopewell, NJ, USA; 14Bristol-Myers Squibb, Princeton, NJ, USA